OpenAI 收购 Orchestra Bio，一个帮助生物制药团队协调药物开发流程的平台，其团队和技术将与生命科学研究工具 Rosalind 整合。Orchestra 的智能体监控研究与时间线，当生产批次失败时可映射哪些试验受影响并汇总应对选项；此前 Anthropic 已于 4 月以约 $400M 股票收购 Coefficient Bio。新药从靶点发现到美国审批平均仍需 10 到 15 年。
OpenAI bought Orchestra Bio, whose AI agents track drug programs.
Until now, Rosalind covered the science: GPT-Rosalind reasons through biology and chemistry, while Rosalind Workbench links models to lab tools and data.
Orchestra targets a different bottleneck, the coordination work that spreads a drug program across departments, contractors and disconnected software.
Its agents monitor studies and timelines, so when a manufacturing batch fails, they map which trials slip and compare responses for program leaders to choose.
Anthropic paid roughly $400M in stock for Coefficient Bio in April, so both labs are now buying specialist biology teams.
Development still averages 10 to 15 years from target to US approval, a clock largely set by trial biology and regulators.
来源：Rohan Paul · x.com